Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJPUDW)

• Drug Name: DS-8273 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Colorectal cancer	2B91.Z	Phase 1	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

• Cross-matching ID:
  PubChem CID: 2734467
  TTD Drug ID: DMJPUDW

Molecule-Related Drug Atlas

Drug(s) Targeting TRAIL receptor 2 (TRAIL-R2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Conatumumab	DM2UOSN	Colorectal cancer	2B91.Z	Phase 2	[4]
Lexatumumab	DMOS5JZ	Solid tumour/cancer	2A00-2F9Z	Phase 2	[5]
Anti-DR5 cells	DMYKZB3	Hepatocellular carcinoma	2C12.02	Phase 1/2	[6]
IGM-8444	DMFJXDZ	Hematologic tumour	2B33.Y	Phase 1	[7]
INBRX-109	DMUNSPI	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
BI 905711	DME9NYV	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
GEN1029	DMV8IWJ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
RhApo2L/TRAIL	DMIAZJ9	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1/2	[4]
LBY-135	DMSRD5U	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[11]
HGS-TR2J	DM0W2TA	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
TRAIL receptor 2 (TRAIL-R2)	TTW20TU	TR10B_HUMAN	Agonist	[3]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] ClinicalTrials.gov (NCT02076451) Open-label Study of DS-8273a to Assess Its Safety and Tolerability, and Assess Its Pharmacokinetic and Pharmacodynamic Properties in Subjects With Advanced Solid Tumors or Lymphomas. U.S. National Institutes of Health.
• [3] First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors. Invest New Drugs. 2017 Jun;35(3):298-306.
• [4] Clinical pipeline report, company report or official report of Amgen (2009).
• [5] National Cancer Institute Drug Dictionary (drug id 528015).
• [6] ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
• [7] Clinical pipeline report, company report or official report of IGM Biosciences.
• [8] Clinical pipeline report, company report or official report of Inhibrx.
• [9] Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist. Mol Cancer Ther. 2021 Jan;20(1):96-108.
• [10] National Cancer Institute Drug Dictionary (drug name Tilogotamab).
• [11] Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors. Invest New Drugs. 2014 Feb;32(1):135-44.
• [12] Enhancement of Glioma Radiation Therapy and Chemotherapy Response with Targeted Antibody Therapy Against Death Receptor 5. Int J Radiat Oncol Biol Phys. 2008 June 1; 71(2): 507-516.